EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Early-stage resectable non-small cell lung cancer in Hungary

Gabriella Gálffy, Réka Hécz, Réka Bujdosó, Eszter Gáspár, Réka Korompay, Judit Hoffer, Szilvia Szécsényi, Celia Blasszauer, Dániel Reibl, Erika Tóth, Krisztina Bogos, László Agócs und 2 weitere

Pathology and Oncology Research · 2025

DOI: 10.3389/pore.2025.1612152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathology and Oncology Research, 2025. Verfasst von Gabriella Gálffy und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncopulmonology, Pulmonology Center of the Reformed Church in Hungary, Törökbálint, Hungary. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study provides a comprehensive analysis of early-stage resectable non-small cell lung cancer (NSCLC) in Hungary, investigating incidence rates, demographic trends, treatment patterns and survival outcomes. We used data from the National Health Insurance Fund (NHIF) spanning 2013–2022, and we analyzed 6,571 patients with available NSCLC histology and no metastasis, who underwent curative surgery within 6 months of diagnosis, and evaluated epidemiological trends and the use of neoadjuvant and adjuvant therapies. For the efficacy analysis, we narrowed the patient cohort to 5,494 patients diagnosed and treated between 2013 and 2019 with at least three-year follow-up data. Key endpoints included overall survival (OS) and disease-free survival (DFS), inferred via time to first subsequent therapy (TFST). Our results revealed a gradual decline in early-stage resectable NSCLC diagnoses, with a significant drop in 2020, likely linked to COVID-19 restrictions. Older age groups (66–75 years) represented a growing proportion of cases, reflecting shifting demographic trends. Among patients with EGFR mutations receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, OS significantly improved compared to those not receiving EGFR-TKI therapy, who are assumed to have wild-type EGFR status (HR = 0.58 (95% CI: 0.47–0.72), p < 0.0001). These findings underscore the importance of early detection, comprehensive biomarker testing and targeted therapies in improving outcomes for resectable NSCLC patients. Future studies with extended follow-up and integration of broader clinical data, including staging and patient comorbidities, are warranted to optimize therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansMaleFemaleAgedHungaryMiddle AgedNeoplasm StagingAdultAged, 80 and overCOVID-19Survival RateNeoadjuvant TherapyIncidenceProtein Kinase InhibitorsFollow-Up Studies

Stichwörter der Autor:innen

EGFR mutationcurative surgeryearly stageepidemiologynon-small cell lung cancer (NSCLC)

Substanzen

Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Oncopulmonology, Pulmonology Center of the Reformed Church in Hungary, Törökbálint, Hungary.
  • AstraZeneca Ltd., Budapest, Hungary.
  • MedicalScan Ltd., Budapest, Hungary.
  • Department of Surgical and Molecular Pathology, National Institute of Oncology, Budapest, Hungary.
  • National Korányi Institute of Pulmonology, Budapest, Hungary.
  • Department of Thoracic Surgery, Semmelweis University, Budapest, Hungary.

Zitieren

APA

Gálffy, G., Hécz, R., Bujdosó, R., Gáspár, E., Korompay, R., Hoffer, J., Szécsényi, S., Blasszauer, C., Reibl, D., Tóth, E., Bogos, K., Agócs, L., Rényi-Vámos, F., & Mórocz, É. (2025). Early-stage resectable non-small cell lung cancer in Hungary. Pathology and Oncology Research. https://doi.org/10.3389/pore.2025.1612152

Vancouver

Gálffy G, Hécz R, Bujdosó R, Gáspár E, Korompay R, Hoffer J, et al. Early-stage resectable non-small cell lung cancer in Hungary. Pathology and Oncology Research. 2025. doi:10.3389/pore.2025.1612152

BibTeX
@article{Glffy2025,
  author = {Gálffy, Gabriella and Hécz, Réka and Bujdosó, Réka and Gáspár, Eszter and Korompay, Réka and Hoffer, Judit and Szécsényi, Szilvia and Blasszauer, Celia and Reibl, Dániel and Tóth, Erika and Bogos, Krisztina and Agócs, László and Rényi-Vámos, Ferenc and Mórocz, Éva},
  title = {Early-stage resectable non-small cell lung cancer in Hungary},
  journal = {Pathology and Oncology Research},
  year = {2025},
  doi = {10.3389/pore.2025.1612152}
}
Kostenlos starten →